GNUV201
GNUV201 is a PD-1 inhibitor with cross-reactivity in humans, mice and monkeys, which effectively blocks the PD-1/PD-L1 interaction. GNUV201 activates T cells and restores their anti-tumor activity, effectively inducing tumor regression. GNUV201 can be used in the research of related diseases such as colorectal cancer, melanoma, pancreatic cancer and colon cancer.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Pureté et documentation
- Références
-
Help & FAQs
Activité biologique
Description
Species Reactivity
Human
In Vitro
GNUV201 and its chimeric precursors bind to CHO cells expressing human PD-1 (EC50=117 pM) and CHO cells expressing mouse PD-1 (EC50=203 pM) with comparable affinities[1].
GNUV201 (15 min, 1 h) blocks the human PD-1/PD-L1 interaction in flow cytometry-based assays with an IC50 of 9.9 nM; it also blocks the murine PD-1/PD-L1 interaction with an IC50 of 6.7 nM[1].
GNUV201 blocks the interaction between human PD-1/PD-L1 in luciferase reporter gene assays, with an IC50 value of 6.3 nM[1].
GNUV201 cross-reacts with mouse PD-1 (EC50=32 pM) and human PD-1 (EC50=28 pM). It has a slower dissociation rate than Keytruda, and exhibits significantly higher binding affinity under acidic pH conditions (Kd=0.9 nM; pH=6.0)[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
GNUV201 inhibits tumor growth in the MC38/hPD-1 knock-in mouse colon cancer model[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:C57BL/6 (female, 7 weeks old, subcutaneous implantation of 1×106 MC38 murine colorectal cancer cells)[1]
-
Dosage:1 mg/kg; 3 mg/kg; 10 mg/kg
-
Administration:i.p.; twice weekly; 2-3 weeks
-
Result:Exhibited dose-dependent tumor growth inhibition with 24% TGI at 1 mg/kg, 59% TGI at 3 mg/kg, and 73% TGI on day 15 post-treatment.
Achieved statistically significant improvement in overall survival, with ~20% of mice surviving without tumor growth at 10 mg/kg.
Gene ID
Accession
Target
PDCD1/PD-1/CD279
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
Product Image
Application
ELISA, FACS, Functional assay
Chemical Information
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureté et documentation
Références
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
GNUV201 Related Classifications
HY-P992357 Related Classifications
Powered by Bioz